RE: RE: RE: what the ....!!!Sanduf - the SP today reflects that WP paid 40 cents, no more imo.
Those that favored a co-development deal for its short term gain are likely sellers today as returns from the Phase 3 plan unlocked through the WP financing will provide a significantly larger upside for shareholders but will take longer to realize. By the second half 2012 an outright sale of the company is the most likely exit strategy - again imo. The price will be north of $1 billion. Of course, the clinicals will need to deliver.
I had thought that removing the financial overhang and providing go forward certainty might have had some positive effect - say to the mid 40s - and that may still be the case within the next few weeks once the disappointed investors leave the stock. However, in the near term (approx. 6 months), look for events like the 24 month Phase 2a results; the 12 month Phase 2b results; filing for the IND; receiving the IND; and milestone payments from Kissei to add shareholder value.
I'm still long, but I understand the motivation of the sellers. It's a FACT that the most expensive financing is the money to get over the finish line.